Drugs / perfluorooctylbromide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04738136 | Sep → Oct 2021 | COVID-19 | SolAeroMed Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT04949386 | Sep → Dec 2021 | COVID-19, long COVID-19 | SolAeroMed Inc. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03041740 Comparator | Jun 2017 → Jun 2019 | bronchopulmonary dysplasia | Children's Hospital of Philadelphia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | perfluorooctylbromide | “S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.” NCT04949386 ↗2“It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2” NCT04738136 ↗ |
| Known as | PFOB | “S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.” NCT04949386 ↗1“It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2” NCT04738136 ↗ |
| Modality | Other / unclassified | “a synthetic surfactant” NCT04738136 ↗ |
| Route | Other | “instilled via side port of endotracheal tube” NCT03041740 ↗ |